| Deucravacitinib Basic information | |
| Product Name: | Deucravacitinib |
| Synonyms: | Tyk2-IN-4;TYK2-IN-4;BMS986165;BMS-986165;BMS986165;6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide;Deucravacitinib;Deucravacitinib(BMS986165);Deucravacitinib(TYK2-IN-4;6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H?)methylpyridazine-3-carboxamide;DeucravacitinibQ:WhatisDeucravacitinibQ:WhatistheCASNumberofDeucravacitinib |
| CAS: | 1609392-27-9 |
| MF: | C20H22N8O3 |
| MW: | 422.45 |
| EINECS: | – |
| Product Categories: | Inhibitors; Pharmaceutical and chemical raw materials; Fine chemical products; Standard products; Pharmaceutical raw materials; |
| Mol File: | 1609392-27-9.mol |
| Introduction | BMS-986165 is a novel oral selective TYK2 inhibitor, and its unique mechanism of action is expected to provide a promising oral option to help patients effectively control their psoriasis. |
| Deucravacitinib Chemical Properties | |
| solubility | DMF：1 mg/ml； DMSO：1 mg/ml； DMSO:PBS (pH 7.2) (1:2)：0.33 mg/ml |
| Storage | Store at -20°C |
| form | Crystalline solid |
| color | From off white to light yellow |